RxDoctor Payments Data

Zalmen Blanck, MD

Clinical Cardiac Electrophysiology · San Antonio, TXNPI 1912976481

Payments from drug & device makers

$27,075in general payments, 2019–2025

Across 387 payments — averaging $69.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Medtronic$10K
  • Abbott$1K
  • Boston Scientific$1K
  • E.r. Squibb & Sons, L.L.C.$885
  • Biosense Webster, Inc.$736
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$5002%
  • Speaking & faculty fees$8,42531%
  • Travel & lodging$5,22119%
  • Food & beverage$12,92948%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,075 in reported general payments places this provider in the 40th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$156,697
Medicare patients
395
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban352$434,846
XareltoRivaroxaban73$97,742
MultaqDronedarone Hcl61$86,552
Dofetilide95$23,497
EntrestoSacubitril/Valsartan22$20,839
Flecainide Acetate372$14,029
Nadolol68$3,226
Amiodarone Hcl188$3,073
SotalolSotalol Hcl153$2,671
Droxidopa24$2,565
Nebivolol Hcl27$2,079
Metoprolol Succinate141$1,676
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$839
Metoprolol Tartrate54$647
Amlodipine Besylate75$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$10,097$434,846352 claims
Johnson & JohnsonXarelto$191$97,74273 claims
Sanofi-aventis U.S. LLCMultaq$145$86,55261 claims
NovartisEntresto$51$20,83922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →